CHP-NY-ESO-1
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CHP-NY-ESO-1, covering 2009-03-03 to 2009-03-03. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers [Phase 1]